Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.
Wenyi ZhangHainan WangPeilei ZhangHongliang LiXiaoli MaHongxing LiuPublished in: Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas (2021)
Inv(16)(p13.1q22) in acute myeloid leukemia (AML) is a common chromosomal abnormality. It leads to the core-binding factor ß-subunit (CBFβ)/smooth muscle myosin heavy chain 11 (MYH11) fusion gene. Different breakpoints were observed in the CBFβ gene at 16q22 and the MYH11 gene at 16p13.1. For this reason, different CBFβ/MYH11 fusion genes are generated, with more than 13 types having been reported to date. Type I CBFβ/MYH11 fusion transcripts are very rare, with only 10 cases being reported to date. This case report describes a primary AML patient with inv(16)(p13.1q22) and a rare type I CBFβ/MYH11 fusion gene. The morphological analysis did not conform to the typical M4eo. Abnormal eosinophils were less than 5%, and there was obvious dysgranulopoiesis. The patient was in hematological and genetic remission for 487 days after the initial chemotherapy cycles. However, the CBFβ/MYH11 fusion had been constantly positive. Moreover, the presence of non-type A fusions may affect its biology and clinical prognosis. Therefore, further studies on understanding its biological and prognostic significance are essential.
Keyphrases
- hypertrophic cardiomyopathy
- acute myeloid leukemia
- genome wide
- copy number
- case report
- smooth muscle
- genome wide identification
- left ventricular
- dna methylation
- squamous cell carcinoma
- transcription factor
- binding protein
- heart failure
- allogeneic hematopoietic stem cell transplantation
- disease activity
- gene expression
- radiation therapy
- atrial fibrillation
- single cell
- genome wide analysis
- acute lymphoblastic leukemia
- rectal cancer